Intestinal schistosomiasis

Summary

Intestinal schistosomiasis (MONDO:0008412) is a disease and 2 clinical trials. Top therapeutic interventions include praziquantel and albendazole. A subtype of schistosomiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intestinal schistosomiasis
Mondo ID	MONDO:0008412
DOID	DOID:0050597
SNOMED CT	240796008
UMLS	C0242497
MedGen	116602
GARD	0024618
Anatomy (UBERON)	UBERON:0000160
Is cancer (heuristic)	no

Disease family

This is a subtype of schistosomiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › schistosomiasis › intestinal schistosomiasis

Related subtypes (6): cercarial dermatitis, neuroschistosomiasis, urinary schistosomiasis, Schistosoma japonicum infectious disease, Schistosoma mansoni infectious disease, Schistosoma intercalatum infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01901484	PHASE2	COMPLETED	Schistosoma Mansoni Morbidity in Children Aged 1-5 Years
NCT01541631	Not specified	UNKNOWN	A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PRAZIQUANTEL	4	2
ALBENDAZOLE	4	1
CHEMBL3264245	0	2